Strategic Acquisition Spinal Modulation was acquired by St. Jude Medical, presenting a clear pathway for channel partners to leverage St. Jude’s broader sales and distribution network to scale the Axium Neurostimulator System in international markets and within post-acquisition initiatives.

Global footprint With operations in the United States, Europe, Australia, and a multinational investor base, there is an opportunity to pursue cross-border sales partnerships, distributor arrangements, and joint marketing programs to accelerate adoption of DRG-targeted SCS therapies.

Clinical momentum The Axium DRG-focused neurostimulation solution has CE Mark and TGA approval and is backed by a pivotal U.S. trial (ACCURATE) for lower limb pain, suggesting strong clinical messaging and key study endpoints to drive conversations with pain centers, hospitals, and surgical groups.

Funding and credibility Significant funding and a high-profile acquisition by a major medical device company enhance credibility for hospital procurement teams and Payers, enabling value-based selling around improved patient outcomes, reduced pain medication use, and potential reimbursement discussions.

Market positioning Position Spinal Modulation's Axium system as a DRG-targeted alternative to traditional dorsal column SCS, appealing to pain management programs seeking targeted, potentially more precise neuromodulation options, with clear upside for expansion in CRPS and nerve injury-related chronic pain markets.